Medline Inc. (MDLN) Return on Invested Capital (ROIC): 5.69%
Is Medline Inc.’s return on invested capital (ROIC) high or low?
Medline Inc.'s return on invested capital (ROIC) of 5.69% is 44% above its 3-year average of 3.95%, near the high end of its 3-year range (0.00%–6.36%).
As of Thursday, June 11, 2026. 5.56% below its 12-month average of 6.03%.
MDLN Return on Invested Capital (ROIC) Chart
MDLN Average Return on Invested Capital (ROIC) Chart
MDLN Current vs Average Return on Invested Capital (ROIC) Chart
MDLN Return on Invested Capital (ROIC) Metrics
RETURN ON INVESTED CAPITAL (ROIC)
5.69%
RETURN ON INVESTED CAPITAL (ROIC) AVG TTM
6.03%
RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y
3.95%
RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y
3.95%
RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y
3.95%
RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y
3.95%
RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y
3.95%
CURRENT VS TTM AVG
-5.56%
CURRENT VS 3Y AVG
+44.05%
CURRENT VS 5Y AVG
+44.05%
CURRENT VS 10Y AVG
+44.05%
CURRENT VS 15Y AVG
+44.05%
CURRENT VS 20Y AVG
+44.05%
MDLN Competitors' Return on Invested Capital (ROIC)
| NAME | MARKET CAP | RETURN ON INVESTED CAPITAL (ROIC) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Medline Inc. (MDLN) | $30.90B | 5.69% | 6.03% | 3.95% | 3.95% |
| IQVIA Holdings Inc. (IQV) | $30.08B | 8.23% | 8.41% | 8.23% | 6.99% |
| Centene Corporation (CNC) | $32.26B | -13.41% | -4.17% | -0.53% | 0.76% |
| Biogen Inc. (BIIB) | $28.94B | 6.62% | 7.71% | 8.64% | 10.90% |
| DexCom, Inc. (DXCM) | $28.92B | 16.61% | 13.40% | 11.07% | 9.62% |
| Zoetis Inc. (ZTS) | $34.27B | 21.54% | 21.87% | 20.30% | 19.27% |
| Veeva Systems Inc. (VEEV) | $26.31B | 9.48% | 9.25% | 9.54% | 11.31% |
| Agilent Technologies, Inc. (A) | $36.21B | 12.57% | 12.57% | 13.57% | 12.73% |
| Waters Corporation (WAT) | $23.21B | 17.57% | 18.00% | 20.73% | 22.79% |
| Mettler-Toledo International Inc. (MTD) | $22.82B | 35.46% | 38.26% | 37.51% | 36.01% |
Capital Efficiency
ROIC
5.7%
ROE
8.6%
Medline Inc. Return on Invested Capital (ROIC) Formula & Definition
ROIC = NOPAT / Invested Capital
Return on invested capital measures the after-tax return a company earns on all capital (debt and equity) invested in the business.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Medline Inc. Return on Invested Capital (ROIC) FAQ
- What is the return on invested capital (ROIC) for Medline Inc. (MDLN)?
- The return on invested capital (ROIC) for MDLN stock is 5.69%.
- Is Medline Inc.'s return on invested capital (ROIC) high or low?
- Medline Inc.'s return on invested capital (ROIC) of 5.69% is 44% above its 3-year average of 3.95%, near the high end of its 3-year range (0.00%–6.36%).
- What is the TTM average return on invested capital (ROIC) for Medline Inc. (MDLN)?
- The TTM average return on invested capital (ROIC) for MDLN stock is 6.03%.
- What is the 3Y average return on invested capital (ROIC) for Medline Inc. (MDLN)?
- The 3Y average return on invested capital (ROIC) for MDLN stock is 3.95%.
- What is the 5Y average return on invested capital (ROIC) for Medline Inc. (MDLN)?
- The 5Y average return on invested capital (ROIC) for MDLN stock is 3.95%.
- What is the 10Y average return on invested capital (ROIC) for Medline Inc. (MDLN)?
- The 10Y average return on invested capital (ROIC) for MDLN stock is 3.95%.
- What is the 15Y average return on invested capital (ROIC) for Medline Inc. (MDLN)?
- The 15Y average return on invested capital (ROIC) for MDLN stock is 3.95%.
- What is the 20Y average return on invested capital (ROIC) for Medline Inc. (MDLN)?
- The 20Y average return on invested capital (ROIC) for MDLN stock is 3.95%.
Medline Inc. Return on Invested Capital (ROIC) History
| DATE | RETURN ON INVESTED CAPITAL (ROIC) |
|---|---|
| 2025-12-31 | 5.69% |
| 2024-12-31 | 6.36% |
| 2023-12-31 | 3.75% |
| 2022-12-31 | 0.00% |
Related Metrics
About Medline Inc.
Medline Inc. is a global manufacturer of medical and surgical products, catering to a broad spectrum of healthcare providers. Their clientele includes hospitals, surgical centers, physician practices, post-acute care facilities, and nursing homes, both domestically and worldwide. The company's operations are divided into two primary divisions: the Medline Brand and Supply Chain Solutions. The Medline Brand division focuses on the production and sourcing of its proprietary medical products, categorized into three key areas: Within Frontline Care, Medline provides a wide array of patient-facing medical and surgical items. This encompasses essentials like wound care treatments, examination gloves, skin and incontinence products, sanitation supplies, various textiles, hand sanitizers, durable medical equipment (DME), patient-specific plastic goods, and decolonization and infection control solutions. The Surgical Solutions category delivers comprehensive product lines for operating rooms and perioperative settings. Offerings range from surgical procedure trays, drapes, and gowns to personal protective equipment (PPE), sterile wraps, various surgical instruments, specialized surgeon's gloves, complete procedure kits, and orthopedic implants. Finally, Laboratory and Diagnostics supplies critical solutions for clinical testing and analysis. This includes point-of-care testing devices, analytical instruments, laboratory consumables, advanced diagnostic equipment, vital signs monitoring systems, and products for anatomic pathology and phlebotomy. The Supply Chain Solutions segment is responsible for sourcing and distributing a diverse portfolio of third-party products, including those from well-known national brands. Beyond distribution, this segment offers comprehensive logistics and supply chain optimization services to clients both domestically and internationally. These optimization services encompass strategic consulting, outsourced management of warehousing and technology, specialized "put-away-ready" packaging, third-party logistics (3PL), inventory rationalization strategies, and efficient route planning. Established in 1966, Medline Inc. maintains its headquarters in Northfield, Illinois.
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- CEO
- James Boyle